Swedish drug tech Biotage acquires U.S.-based PhyNexus for $21.5M

Swedavia has sold a future Comfort hotel at Stockholm Arlanda Airport to boost the hotel's competitive edge and meet growing traveler numbers.
Swedish pharma technology company Biotage snapped up U.S.-based PhyNexus in a deal valued at $21.5 million. (Thomas Fabian)

Swedish pharma technology company Biotage snapped up U.S.-based PhyNexus in a deal valued at $21.5 million.

The acquisition is expected to bolster Biotage’s presence as a separations company within the growing biomolecule arena. The company said it will now be able to provide an automation platform based on Dual flow Chromatography and patented tip technology for higher throughput purification of biomolecules such as proteins, plasmids and antibodies at the lab-scale.

“This transaction enables PhyNexus’ products to reach a larger global market through Biotage’s direct sales organization, at the same time as Biotage obtains access to customers in industries where Biotage historically has not been active,” Torben Jörgensen, Biotage’s chief executive, said in a statement. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The company expects the platform has the potential to address a growing multibillion-dollar market, and that the platform will provide enhanced high-throughput workflow approaches for clinical, forensic, food and environmental testing.

Financing for the deal was conducted with a combination of newly issued shares of Biotage and cash.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.